Fifth Third Wealth Advisors LLC Sells 536 Shares of Gilead Sciences, Inc. $GILD

Fifth Third Wealth Advisors LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,763 shares of the biopharmaceutical company’s stock after selling 536 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,415,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth about $29,000. Colonial Trust Advisors boosted its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital boosted its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.4%

NASDAQ:GILD opened at $117.18 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $145.40 billion, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $84.17 and a 52 week high of $121.83. The firm has a 50-day moving average price of $114.65 and a two-hundred day moving average price of $110.26.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Citigroup upped their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $118.08.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock worth $9,402,130. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.